This section was clarified to direct questions regarding eligibility to the study data manager.
|
|
- Ferdinand Jackson
- 5 years ago
- Views:
Transcription
1 For Protocol Amendment 8 to: RTOG 0839, Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer NCI/Local Protocol #: RTOG-0839/RTOG 0839 NCI Protocol Version Date: October 9, 2014 Global Title pages Eligibility Checklist Change References to RTOG were replaced with NRG Oncology. References to the RTOG Biospecimen Resource were replaced with NRG Oncology Biospecimen Bank. The Principal Investigator/Medical Oncology s institutional affiliation and contact information was updated. On the 2 nd title page, this amendment was added to the Document History table. The CTSU Address and Contact Information table was deleted from the 3 rd title page. The third sub-question under question 1 of the Eligibility Checklist was amended to clarify that the diameter of involved N2 nodes are 3.0 cm. This section was clarified to direct questions regarding eligibility to the study data manager. This section was amended to clarify that the diameter of involved N2 nodes cannot exceed 3.0 cm. This section was updated to reflect new Imaging and Radiation Oncology Core (IROC) processes/logistics This section was updated to reflect new IROC processes/logistics and These sections were updated to reflect new IROC processes/logistics. 5.5 Pre-registration requirements for surgeon credentialing contacts were updated The first full paragraph was amended to replace the reference to a Cooperative Group to a lead protocol organization. In the final bullet, obsolete instructions for enrolling as an RTOG member site were removed. 6.0 The note was deleted to amend this section to current standard text This section was amended for clarity and These sections were amended for clarity , 6.5.2, These sections were amended for clarity.
2 Global Change References to RTOG were replaced with NRG Oncology. References to the RTOG Biospecimen Resource were replaced with NRG Oncology Biospecimen Bank RTQA please provide brief rationale added for clarification 7.0 The obsolete reference to the RTOG Procedures Manual was removed. 7.3 The reference to the package insert and investigator brochure was removed CTEP s AE reporting requirements were updated The section was amended for clarification to reflect changes made in 6. For Consent Amendment 8 to: RTOG 0839, Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer NCI/Local Protocol #: RTOG-0839/RTOG 0839 NCI Protocol Version Date: October 9, 2014 Global Change Due to the transition to the National Clinical Trials Network (NCTN), Radiation Therapy Oncology Group, RTOG Headquarters, and RTOG were replaced with NRG Oncology, or deleted, as appropriate, throughout the consent form. Possible Side Effects of Carboplatin The table was replaced with the most recently updated table version dated May 7, Possible Side Effects of Panitumumab Possible Side Effects of Radiation Therapy to the Lungs The table was replaced with the most recently updated table version dated March 13, The title of the table was changed from Possible Side Effects of Radiation Therapy to the Chest to Possible Side Effects of Radiation Therapy to the Lungs. The list of side effects were revised to include the most current information.
3 For Protocol Amendment 7 to: RTOG 0839, Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer NCI/Local Protocol #: RTOG-0839/RTOG 0839 NCI Protocol Version Date: March 10, 2014 Global Title pages Schema page 5.1.1, 5.1.2, 5.2.2, 5.3.1, 5.3.3, 5.6 Change As required by CTEP, references to Adverse Event Reporting System (AdEERS) have been changed to CTEP Adverse Event Reporting System (CTEP-AERS) throughout the protocol. As required by CTEP, Radiation Therapy Oncology Group was replaced NRG Oncology on all title pages. On the 2 nd title page, this amendment was added to the Document History table. As required by CTEP, Radiation Therapy Oncology Group was replaced NRG Oncology. In these sections, Radiologic Physics Center (RPC) was updated to IROC (Imaging and Radiation Oncology Core) Houston, and when included, the web address for RPC was amended to the web address for IROC Houston In the 2 nd paragraph, the RTOG was updated to IROC. 6.9 Throughout this section, RTOG was updated to IROC Philadelphia-RT This section was amended to include the rare risk of Stevens-Johnson syndrome and toxic epidermal necrolysis, as received from the pharmaceutical supporter, Amgen The last paragraph under Preliminary Dosimetry Information was updated. Appendix VI The 4 th paragraph describing the rare risk of Steven-Johnson syndrome and toxic epidermal necrolysis was added to be consistent with changes made in
4 For Consent Amendment 7 to: RTOG 0839, Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer NCI/Local Protocol #: RTOG-0839/RTOG 0839 NCI Protocol Version Date: March 10, st page The version date was amended to correspond to the amendment of the protocol. What side effects or risks can I expect from being in the study? Under Possible Side Effects of Panitumumab, the rare risk of Stevens-Johnson syndrome and toxic epidermal necrolysis was added. The risk/benefit profile for this agent is unchanged. At CTEP s request, the Table Version Date and the risks of paclitaxel were amended.
5 For Protocol Administrative Update of RTOG 0839, Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer NCI/Local Protocol #: RTOG-0839/RTOG 0839 NCI Protocol Version Date: 11/26/14 (Update broadcast: 1/7/14) 12.2 Change The name of the form for submission of digital data via TRIAD was updated to DDSI.
6 For Protocol Amendment 6 to: RTOG 0839, Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer NCI/Local Protocol #: RTOG-0839/RTOG 0839 NCI Protocol Version Date: 11/26/13 Title pages Table of Contents Change On the 2 nd title page, this amendment was added to the Document History table. A 3 rd title page was added in order to update the protocol with the current CTSU contact information table (to be consistent with s 5.6 and 5.7). The table was regenerated to include the addition of The 2 nd sentence was updated to current RTOG standard text , 5.3.2, 6.0, 6.1.3, 6.6, 6.9, 12.1, and 12.2 RTOG is now using TRIAD to collect RT digital data. TRIAD provides sites participating in RTOG clinical trials with a secure method to transmit DICOM RT and other digital data. TRIAD anonymizes and validates the images and information objects as they are transferred via the internet. The first 2 paragraphs were added to update the protocol with access requirements for OPEN and TRIAD. The 3 rd paragraph was deleted. These sections were updated to include logistics for TRIAD for RT digital data submission The 3 rd paragraph was added to update this section to current RTOG RTQA text. 5.4 This section was added to update the protocol with instructions regarding submission of digital RT data using TRIAD (and subsequent sections were appropriately renumbered). 5.6 In the 2 nd paragraph, the phone number for PMB was updated. 6.0 and The timeframe for start of protocol treatment in these sections was expanded from 7 to 14 days to allow more flexibility for sites. In the 2 nd paragraph, the drug supply was corrected from patient specific to study specific. Below the table, the phone number for the FCS Help Desk was updated The 3 rd paragraph was updated with CTEP s required text and These sections were updated to current RTOG Biospecimen Resource text. In the 2 nd row under Submitted as, a parenthetical phrase was added to update the table to current RTOG Biospecimen Resource text. In the 2 nd paragraph, the phrase, Trackable FFPE and All, was added to update the section to current RTOG Biospecimen Resource text.
7 11.2 Appendix V Change In the 1 st paragraph, the link to RECIST was updated. The 2 nd paragraph was formatted as , titled Radiographic Response, and the text was updated to RECIST, v. 1.1 to be consistent with the 1 st paragraph. Subsequent sections were appropriately renumbered. The 2 nd and 3 rd paragraphs were updated to current RTOG Biospecimen Resource text.
8 For Consent Amendment 6 to: RTOG 0839, Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer NCI/Local Protocol #: RTOG-0839/RTOG 0839 NCI Protocol Version Date: 11/26/13 1 st page The version date was amended to correspond to the amendment of the protocol. What side effects or risks can I expect from being in the study? Will my medical information be kept private? Under Possible Side Effects of Radiation Therapy to the Chest, in each section of the table, the phrase, In 100 people receiving Carboplatin, was corrected to In 100 people receiving radiation therapy. No side effects were changed. CTSU was added to the organizations that may access medical records to be consistent with s 5.6 and 5.7 of the protocol.
9 For Protocol Amendment 5 to: RTOG 0839, Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer NCI/Local Protocol #: RTOG-0839/RTOG 0839 NCI Protocol Version Date: 7/24/13 1 st Title page Change Dr. Edelman s affiliation and contact information were amended. 2 nd Title page This amendment was added to the Document History table. The version date of the protocol was bolded in the Document History table to update the protocol to current RTOG standards. Eligibility Checklist On pages 3 and 4, questions 1 through 27 were amended to be consistent with OPEN registration. 3.0 The 2 nd sentence was added to update this section to current RTOG standard text An alternative to the formula to determine the predicted post-resection FEV1, segment counting, was added The last sentence of the 2 nd paragraph was updated to current RTOG standard text This section was updated to current RTOG standard text This section was updated to current RTOG standard text and The 2 nd paragraph was amended and the 3 rd paragraph was deleted to update this section to current RTOG standard text. These sections were updated to current RTOG standard text. 5.6 This section was amended for OPEN Registration. 6.0 The 2 nd sentence was added to provide instructions regarding the pre-plan. 7.4 and 7.5 The 1 st sentence was added to update each section to current RTOG standard text , , and Instructions regarding a Paclitaxel Infusion Reaction were added in the table and in footnote d below the table (the subsequent footnote was appropriately re-lettered as e ). Instructions regarding a Paclitaxel Infusion Reaction were added in the table and in footnote c below the table. These sections were updated to current RTOG standard text.
10 Change This section was updated to current CTEP text This section was updated to current RTOG standard text The 4 th bulleted item was amended. 10.2, , , and These sections were updated to current RTOG Biospecimen Resource text In the table, in the 2 nd column for DNA, a note was added. Appendix V Throughout this appendix, the abbreviation for Specimen Transmittal (STF), was corrected to ST. In addition, the abbreviation for Specimen Transmittal Form (STF), was corrected to ST Form.
11 For Consent Amendment 5 to: RTOG 0839, Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer NCI/Local Protocol #: RTOG-0839/RTOG 0839 NCI Protocol Version Date: 7/24/13 1 st page The version date was amended to correspond to the amendment of the protocol. What side effects or risks can I expect from being in the study? About Using Tissue for Research The side effects of radiation to the chest were reformatted to be consistent with CTEP s current condensed risk profiles. The side effects for paclitaxel and carboplatin were amended to CTEP s current condensed risk profiles. The side effects for panitumumab were amended to incorporate CTEP s risk profile for this agent. The risks are comparable to the package insert. Under Risks, 5 paragraphs were added to update this section to standard RTOG text.
12 For Protocol Amendment #4 to: RTOG 0839, Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer NCI/Local Protocol #: RTOG 0839 NCI Protocol Version Date: March 21, 2013 (Broadcast date: April 8,, 2013) Change Global To comply with CTEP s new formatting/document requirements, the protocol was reformatted and the sample consent was removed from the appendices. The appendices were appropriately renumbered throughout the protocol. The informed consent continues to be available via MS Word on the protocol documents section of the main protocol page. 1.1 A header was added to this section 2nd Title Page The document history table was updated with the date for Amendment nd paragraph, the last sentence was revised for clarity. Systematic mediastinal lymph node evaluation replaced mediastinal nodal dissection This paragraph was amended to clarify the credentialing process This section was amended to provide clarity The table for Arms 1 and 2 was amended for clarity. Day 21 has been changed to Day This section was updated to align with RTOG standard text for investigational agents The reference to NCI Guidelines was updated The Note in the table was deleted to be consistent with AdEERS reporting requirements.
13 Change 8.2 The surgical techniques have been updated throughout this section to align with current practice. 8.3 The phrase typically, Lasix 20 mg bid is used daily was removed Muscle flaps was replaced with soft tissue coverage for clarification An unacceptable deviation was added to the list The process for submitting final dosimetry information was updated The ITC contact information was updated. References The reference Gray, RJ. was amended. Appendix I The table was updated to allow within 6 weeks for tumor location, type and size. Appendix VII The Thoracic Surgeon Questionnaire was amended to align with the surgical requirements for this study.
14 For Protocol Consent Amendment #4 to: RTOG 0839, Randomized Phase II Study of Pre- Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer NCI/Local Protocol #: RTOG 0839 NCI Protocol Version Date: March 21, 2013 (Broadcast date: April 8, 2013) Version date A version date was added to the informed consent form per current RTOG standard. What are the costs of taking part in this study? The link is broken and has been removed.
15 SUMMARY OF CHANGES Amendment 3, Version Date: August 16, 2012 RTOG 0839, Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer Study Chair: Martin J. Edelman, , RTOG 0839 has been amended as follows: During the review of a recent serious adverse event, it was found that the case had 2 mediastinal nodes that exceeded the 3 cm limit; this limit already existed in the protocol. The case s lung V20 also exceeded the limits set forth in the protocol. It was felt that these issues led to the development of the grade 5 adverse event. The protocol was amended to emphasize the already existing text regarding the mediastinal nodal size limit as well as the lung V20 constraints, as follows: Schema page: A symbol ( ) was added in both treatment arms next to Concurrent RT, referencing a footnote instructing investigators to see s 6.0 and 6.6 regarding the V20. Eligibility Checklist: Page 1: A subquestion was added under Question 1 concerning the largest diameter of any involved node to be consistent with Page 4: Question 29 was added : The phrase, the maximum nodal diameter not to exceed 3.0 cm, was clarified to the maximum nodal diameter cannot exceed 3.0 cm. 6.0: A note was added regarding required RT pre-planning : The former last paragraph was amended and bolded for emphasis, and an additional bolded paragraph was added below to provide further instructions to investigators regarding the V20. Other Changes 1 st title page: Study Chairs was amended to the current RTOG standard text, Study Team. In addition, the Senior Statistician was amended from Dr. Dignam to Dr. Hu. 2 nd title page: The Version Date was deleted to amend the protocol to the current RTOG standard of bolding the version date of the protocol in the Document History table. In addition, this amendment was added to the Document History table. Eligibility Checklist, p. 3: Under the heading, the 2 nd sentence was added to be consistent with instructions in was deleted, as it was redundant with , and subsequent sections were appropriately renumbered : In the 1 st paragraph, the phrase, stereotactic body radiation therapy (SBRT), was deleted because this study does not involve that treatment technique : In the 1 st sentence, REB was deleted, as the study is open to U.S. sites only. The link to the CTSU-IRB Certification Form was updated concerning translation of documents was deleted, as the study is open to U.S. sites only, and this text does not apply; U.S. sites generally follow a short form method for consenting non-english speaking patients (unless they serve a large population of these patients) : Electa was corrected to Elekta.
16 Other Changes (continued) 6.6.2: CTV1 was corrected to CTV. RTOG 0839, Amendment 3, page : PTV was added to the list of DVH required : In the 2 nd paragraph, the sentence beginning, Any pregnancy, was amended to current RTOG standard text : The phrase, and brain MRI with contrast, was moved to a separate section, (and subsequent sections were appropriately renumbered), to clarify that it is an assessment separate from those in In addition, FDG-PET was corrected to FDG-PET/CT. Appendix I: The heading, When you are finished the additional chemotherapy, was corrected to When you are finished with the additional chemotherapy. In addition, under this heading, the bone scan was deleted, as this assessment is not required in follow up. Appendix II: Under Follow Up, the X for the bone scan was deleted, as this assessment is not required in follow up.
17 SUMMARY OF CHANGES Amendment 2, Version: February 9, 2012 RTOG 0839, Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer Study Chair: Martin J. Edelman, , RTOG 0839 has been amended as follows: The following changes were made to the title pages: Dr. Donington s fax number was updated. Dr. Loo was added as the Imaging Co-Chair. Dr. Dignam replaced Dr. Bae as the Senior Statistician. The Activation Date and Update Date were deleted, as this information is provided in the Document History table (the updated Version Date was retained for clarity). The Document History table was updated for this amendment. 1.5: In the 3 rd paragraph, the description of the FLEX trial was corrected to cisplatin, vinorelbine, and cetuximab versus cisplatin and vinorelbine : The 4 th and 5 th sentences were added to provide instructions to sites regarding PET/CT images, reports, and assessment forms : In the note, the phrase, FDG-PET scan, was corrected to FDG-PET/CT scan. 5.4: In the 2 nd paragraph, Dr. Donington s address was corrected. This correction also was made on the 3 rd page of Appendix VIII, Thoracic Surgeon's Questionnaire was amended to current RTOG standard text was added to amend the protocol to current RTOG standard text : The phrase, 6-18 MV beams was corrected to 6-10 MV beams. 7.10: The 5 th paragraph was added to amend the protocol to current RTOG standard text. 7.11: The title of the table and the table were amended to current CTEP requirements : In the 6 th bulleted item, a sentence regarding PET/CT images, reports and assessments forms was added to the 3 rd subsection : The phrase, and medical oncologist was deleted, as this individual does not have to review and sign all post-surgical forms. 10.7: The street address for the RTOG Biospecimen Resource was updated. This change also was made in Appendix VI. 10.8: The link to the Reimbursement and Case Credit Schedule was corrected. 10.9: This section was previously numbered as 10.8, and this was corrected. s and : The last sentence regarding PET/CT images, reports and assessments forms was added to each section.
18 RTOG 0839, Amendment 2, Page 2 The following changes were made to 12.1: The phrase, Pre-Study PET/CT Scan was clarified to Pre-Treatment PET/CT Scan. A note was added to the required timeframe for the Pre-Treatment PET/CT Scan to provide instructions to sites. The Treatment Summary Form was re-named Radiotherapy Form (T1). A sentence was added below the Post-RT PET/CT scan and Report to instruct sites that scans must be on a CD and in DICOM format. In addition, a reference to was deleted. A reference to and a note were added to the required timeframe for the Post-RT PET/CT Scan and Report. 12.2: The form designations, (C1, C3), next to CT data, critical normal structures, all GTV, CTV, and PTV contours were deleted, as these designations are no longer RTOG standard : The 2 nd, 3 rd, and 5 th paragraphs were amended to provide further details regarding assessment of PET/CT scan data to predict outcome. References: A citation for Wahl 2009, referenced in the amended 5 th paragraph of , was added. The following changes were made in Appendix I: Under When you are finished the additional chemotherapy, an evaluation of your overall physical condition, was added to the 1 st and 2 nd bulleted items to be consistent with changes made in Appendix II. Under Will my medical information be kept private?, the 3 rd and 4 th paragraphs were added to amend the sample consent to the current NCI template. Under About Using Tissue, Blood, and Urine for Research, in the 2 nd paragraph, the title for and the link to the information sheet were updated. Under Where can I get more information?, the TTY number was deleted at NCI s request. Appendix II: For the Zubrod Performance Status, the assessment During Consolidation Treatment was corrected from Weekly to q 3 wks, and the assessment was added in both Follow Up columns. Appendix VIII: On the 3 rd page, Dr. Donington s fax number was updated.
19 SUMMARY OF CHANGES Update: July 6, 2011 (Broadcast 7/6/11) RTOG 0839, Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer Study Chair: Martin J. Edelman, , RTOG 0839 has been updated as follows: Eligibility Checklist, page 2: Question 11 was updated to be consistent with changes made to in amendment 1.
20 SUMMARY OF CHANGES Amendment 1, June 24, 2011 (Broadcast: 7/6/11) RTOG 0839, Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer Study Chair: Martin J. Edelman, , RTOG 0839 has been amended as follows: Eligibility Checklist, page 4: Question 28 was amended to be more specific and to be consistent with the following subquestion : The timeframe for the pathological confirmation of N2 status was expanded to 12 weeks prior to registration to allow institutions more flexibility in meeting this requirement. This change also was made in question 1 (3 rd subquestion) on page 1 of the Eligibility Checklist, 8.1.1, and in Appendix II was reformatted into 2 sections for clarity: for the required MRI with contrast (or CT scan with contrast, if medically indicated), and for the required CT scan with contrast of the lungs and upper abdomen : A timeframe of 6 weeks of registration was added for the whole body FDG-PET scan. This information also was added to : In the last sentence, the phrase, and/or, was corrected to and. 5.4 was amended to request institutions to (vs. fax) the Thoracic Surgeon s Questionnaire to Dr. Donington. This change also was made in Appendix VIII : The link to the Certification Form was updated : In the heading, the word, only was added after U.S. Institutions to clarify that panitumumab is available only to these sites. In addition, the description of the placement of the SASF on the RTOG web site was amended. These changes also were made in : The link to the Password Authorization Form and the address for RTOG web support were updated. 7.10: In the 2 nd paragraph, the link to the RTOG web site was updated : The last 3 sentences were added to provide institutions and investigators with documentation requirements for patients who do not undergo resection and with a definition of a protocol violation , Surgical Quality Assurance Reviews, was amended for clarity was amended to read that Dr. Donington will perform a quality assurance review on each case after complete data has been received at RTOG Headquarters for that case : Under Deviations Unacceptable, the last bulleted item was amended to include documentation of decline in medical condition to be consistent with changes in s 10.3 and 10.4 were amended to current RTOG Biospecimen standards. Continued on next page
21 RTOG 0839, Amendment 1, Page was added to update the protocol to current RTOG Biospecimen standards, and subsequent sections were appropriately renumbered was amended to current RTOG standard text. 10.8: The link to RTOG Patient Tissue Consent Frequently Asked Questions was updated : In the 1 st sentence, the reference to was corrected to : Next to Hard copy isodose distributions for total dose plan, the phrase as described in QA guidelines, was deleted, as was the corresponding note. This is a correction, as these guidelines are not available. The following changes were made in Appendix I: Under What will happen if I take part in this research study? and If you are in group 2, the timeframe for panitumumab was corrected from 7 to 6 weeks. Under When you are finished the additional chemotherapy, an MRI of the brain (or CT scan if indicated was added to be consistent with Appendix II. The risks associated with paclitaxel and carboplatin were amended to be more consistent with the sample consents of other active RTOG clinical trials involving these agents. Under the Less Likely, but Serious risks associated with panitumumab, in the last bulleted item, lunch damage was corrected to lung damage. Under About Using Tissue, Blood, and Urine for Research, in the 1 st paragraph, the phrase, or have had, was added prior to a biopsy. In the 2 nd paragraph, the title and link to NCI s information sheet were updated. The following changes were made in Appendix II: Under the follow-up timeframe for the MRI or CT with contrast of the brain, the X was replaced with If clinically indicated. An MRI or CT of the brain is not required at followup visits unless clinically indicated. Under Assessments, the Chest X-ray was amended to +/- optional chest x-ray to be consistent with Appendix VI was updated to current RTOG Biospecimen Resource standards. Appendices VII and VIII were deleted, as this information is included in the updated Appendix VI, and subsequent appendices were renumbered appropriately on the Index page and throughout the protocol.
22 SUMMARY OF CHANGES Update: February 11, 2011 (Broadcast 2/11/11) RTOG 0839, Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer Study Chair: Martin J. Edelman, , RTOG 0839 has been updated as follows: Title page: Dr. Dicker s address was updated. In addition, a Document History table was added to update the protocol to current RTOG standards. 5.4 was updated to indicate a change in process. Dr. Donington will the reviewed site Thoracic Surgeon s Questionnaire to RTOG HQ as well as CTSU. The last page of Appendix X was updated to be consistent with this change. Appendix X: A sentence and parenthetical reference to 5.4 were added to the first paragraph to clarify that surgeon credentialing is a pre-registration requirement.
23 SUMMARY OF CHANGES Update: December 23, 2010 RTOG 0839, Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer Study Chair: Martin J. Edelman, , RTOG 0839 has been updated as follows: 5.4 was updated to indicate a change in process. Dr. Donington will her approval of a site s Thoracic Surgeon s Questionnaire to CTSU. Appendix X was updated to be consistent with this change : Information about the shipment of the study agent was updated : This section was amended as required by CTEP to instruct sites to report AML or MDS via AdEERS.
Page 1, column 2, entry for Lech Papiez: Line 2: Former was added in front of Medical Lines 4-7 of his entry were deleted.
For Amendment 7 to: RTOG 0813, Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Patients NCI/Local Protocol #: RTOG-0813/RTOG 0813 NCI Protocol Version Date: June 8, 2015 (Broadcast
More informationNCI Protocol Version Date: October 11, 2016 (Broadcast: November 7, 2016) The protocol version date was updated
For Protocol Amendment 8 to: RTOG 1106 / ACRIN 6697, Randomized Phase II trial of individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT And Modern Technology in Locally Advanced Non-Small
More information3.1.4 The phrase, and only focal nuclear, was clarified to and/or only focal nuclear.
For Protocol Amendment 3: RTOG 1221, Randomized Phase II Trial of Transoral Endoscopic Head And Neck Surgery followed by Risk-Based IMRT and Weekly Cisplatin versus IMRT and Weekly Cisplatin for HPV Negative
More informationNCI/Local Protocol #: RTOG-1005/RTOG NCI Protocol Version Date: July 31, 2014
For Protocol Amendment 4 to: RTOG 1005, A Phase III Trial of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost
More informationNCI/Local Protocol #: RTOG-0521/RTOG NCI Protocol Version Date: December 22, 2014 (Broadcast date: 2/2/2015)
For Protocol Amendment 7of RTOG 0521, A Phase III Protocol of Androgen Suppression (As) And 3DCRT/IMRT Vs. As And 3DCRT/IMRT Followed By Chemotherapy With Docetaxel And Prednisone For Localized, High-Risk
More informationNCI/Local Protocol #: RTOG-0522/RTOG NCI Protocol Version Date: January 26, 2016
For Amendment 10 to: RTOG 0522, A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery
More informationFor Protocol Amendment 5 of: RTOG 0938, A Randomized Phase II Trial of Hypofractionated Radiotherapy For Favorable Risk Prostate Cancer
Section For Protocol Amendment 5 of: RTOG 0938, A Randomized Phase II Trial of Hypofractionated Radiotherapy For Favorable Risk Prostate Cancer NCI/Local Protocol #: RTOG-0938/RTOG 0938 NCI Protocol Version
More informationFor Protocol Amendment 3 of: NRG-BR001, A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
For Protocol Amendment 3 of: NRG-BR001, A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases NCI/Local Protocol #: NRG-BR001/NRG BR001 NCI Protocol Version
More informationThe document history table was updated to include Amendment 6.
For Protocol Amendment #6 to: RTOG 0913, Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma NCI Protocol
More informationSUMMARY OF CHANGES Amendment 6, Version Date: March 29, 2010 [Broadcast: April 8, 2010]
Amendment 6, Version Date: March 29, 2010 [Broadcast: April 8, 2010] RTOG 0233, "A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation
More informationSUMMARY OF CHANGES Amendment 3: August 17, 2011 (Broadcast: August 25, 2011)
Amendment 3: August 17, 2011 (Broadcast: August 25, 2011) RTOG 0529, A Phase II Evaluation of Dose-Painted IMRT in Combination with 5-Fluorouracil and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma
More informationSUMMARY OF CHANGES Amendment 5, Version Date: March 24, 2010 Broadcast: 4/6/10
Amendment 5, Version Date: March 24, 2010 Broadcast: 4/6/10 RTOG 0239, "A Phase II Study Of Accelerated High Dose Thoracic Irradiation With Concurrent Chemotherapy For Patients With Limited Small Cell
More informationNavigating Alliance Protocols
Navigating Alliance Protocols Morgen Alexander-Young, MPH Alliance Central Protocol Operations Program Alliance Spring 2017 Group Meeting Alliance Protocol History Alliance for Clinical Trials in Oncology
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationALL PRINCIPAL INVESTIGATORS/NURSES/DATA MANAGERS RE: PROTOCOL GOG-0233 ACRIN 6671, REVISION # 9 & #10
TO: FROM: ALL PRINCIPAL INVESTIGATORS/NURSES/DATA MANAGERS LEAH MADDEN PROTOCOL SECTION DATE: JUNE 27, 2011 RE: PROTOCOL GOG-0233 ACRIN 6671, REVISION # 9 & #10 Protocol Title: Utility of Preoperative
More informationClinical Trial Credentialing:
IROC Mission Clinical Trial Credentialing: Provide integrated radiation oncology and diagnostic Where imaging to Start quality and control programs in support of the NCI s NCTN Network thereby Resources
More informationReview of Workflow NRG (RTOG) 1308: Phase III Randomized Trial Comparing Overall Survival after Photon versus Proton Chemoradiation Therapy for
Review of Workflow NRG (RTOG) 1308: Phase III Randomized Trial Comparing Overall Survival after Photon versus Proton Chemoradiation Therapy for Inoperable Stage II-IIIB NSCLC 1 Co-Chairs Study Chair: Zhongxing
More informationThis amendment was added to the document history table. Contact information was updated for Dr. Aldape.
For Protocol Amendment 7 to: RTOG 0837, Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib Versus Conventional Chemoradiation
More informationIROC Imaging and Radiation Oncology Quality Assurance for the NCTN
IROC Imaging and Radiation Oncology Quality Assurance for the NCTN Fran Laurie IROC Rhode Island November 6, 2015 Presentation Objectives!! What is IROC!! Understand IROC s organization and services!!
More informationThe Document History Table was updated to include this amendment. The CTSU contact information table was updated.
For Protocol Amendment #8 to: RTOG 1205, Randomized Phase II Trial of Concurrent Bevacizumab and Re Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma NCI/Local Protocol #: RTOG
More informationNSABP B-55/BIG Lynne Suhayda, RN, MSEd. Director, Clinical Coordinating Department. NRG Oncology - Pittsburgh, Pennsylvania
NSABP B-55/BIG 6-13 Lynne Suhayda, RN, MSEd. Director, Clinical Coordinating Department NRG Oncology - Pittsburgh, Pennsylvania NRG Oncology Meeting July 15, 2016 Lynne Suhayda, RN, MSEd. No Financial
More informationNSABP PROTOCOL B-39B RTOG PROTOCOL 0413
NSABP PROTOCOL B-39B RTOG PROTOCOL 0413 (A RANDOMIZED PHASE III STUDY OF CONVENTIONAL WHOLE BREAST IRRADIATION WBI) VERSUS PARTIAL BREAST IRRADIATION (PBI) FOR WOMEN WITH STAGE 0, I, OR II BREAST CANCER
More informationRPC Liver Phantom Highly Conformal Stereotactic Body Radiation Therapy
RPC Liver Phantom Highly Conformal Stereotactic Body Radiation Therapy Guidelines for Planning and Irradiating the RPC Liver Phantom. Revised Dec 2005 Credentialing for this protocol requires four steps:
More informationThe Clinical Research E-News
Volume 3: ISSUE 11: June 15, 2011 The Clinical Research E-News Reminder: CRA Quarterly Meeting, Philadelphia, PA: 10-11am on Wednesday June 22nd- Virtual Meeting: dial information attached in a separate
More informationInternational RT Clinical Trial Group Membership & Quality Control BY DR YING XIAO
International RT Clinical Trial Group Membership & Quality Control BY DR YING XIAO Disclosures The Department of Radiation Oncology at Hospital of University of Pennsylvania has a research agreement with
More informationNCI/Local Protocol #: RTOG NCI Protocol Version Date: June 3, 2016
For Protocol Amendment #12 to: RTOG 0929, A Randomized Phase I/II Study of ABT-888 in Combination With Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma NCI/Local Protocol #: RTOG 0929 NCI
More informationADVANCED TECHNOLOGY CONSORTIUM (ATC) CREDENTIALING PROCEDURES FOR LUNG BRACHYTHERAPY IMPLANT PROTOCOLS
ACOSOG-RTOG Lung Brachytherapy QA Page 1 of 8 ADVANCED TECHNOLOGY CONSORTIUM (ATC) CREDENTIALING PROCEDURES FOR LUNG BRACHYTHERAPY IMPLANT PROTOCOLS FACILITY QUESTIONNAIRE Institutions wishing to enter
More informationThe Clinical Research E-News
Volume 4: ISSUE 6: August 28, 2012 The Clinical Research E-News Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Trials Opened at
More informationRTOG DOSIMETRY DATA SUBMISSION
Radiation Therapy Oncology Group American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103-3604 (215) 574-3189 (800) 227-5463 Ext. 4189 (215) 928-0153 Fax Phoenix, Arizona RTOG
More informationSBRT Credentialing: Understanding the Process from Inquiry to Approval
SBRT Credentialing: Understanding the Process from Inquiry to Approval David Followill, Ph.D. (presented by Andrea Molineu, M.S.) IROC Houston QA Center July 15, 2015 What is credentialing? Verification
More informationCANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I Changes and Clarifications 16 th Edition April 15, 2016 Quick Look- Updates to Volume
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 2: ISSUE 19: October 13, 2010 Coming soon: RTOG 0929, A Randomized, Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant)
More informationImplementing SBRT Protocols: A NRG CIRO Perspective. Ying Xiao, Ph.D. What is NRG Oncology?
Implementing SBRT Protocols: A NRG CIRO Perspective Ying Xiao, Ph.D. What is NRG Oncology? One of five new NCI-supported National Clinical Trials Network (NCTN) groups. NCTN officially started March 1,
More informationLeveraging Innovation to Design Future Clinical Trials. Outline. Multi-Institutional Research 7/15/2015
Leveraging Innovation to Design Future Clinical Trials Jeff M. Michalski, MD, MBA, FACR, FASTRO The Carlos A Perez Distinguished Professor of Radiation Oncology Outline National Clinical Trial Network
More informationLung Spine Phantom. Guidelines for Planning and Irradiating the IROC Spine Phantom. MARCH 2014
Lung Spine Phantom Guidelines for Planning and Irradiating the IROC Spine Phantom. MARCH 2014 The study groups are requesting that each institution keep the phantom for no more than 2 week. During this
More informationCredentialing for Clinical Trials -IGRT. Evidence Based Radiation Oncology. Levels of Clinical Evidence. Why Credentialing?
Acknowledgements Credentialing for Clinical Trials -IGRT Invitation from Organizers RTOG Headquarter QA Team ATC Collaborators Evidence Based Radiation Oncology Clinical Trials From Collaborative Groups
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 7: ISSUE 1: January 16, 2015 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials
More informationNRG Oncology Lung Cancer Portfolio 2016
NRG Oncology Lung Cancer Portfolio 2016 Roy Decker, MD PhD Yale Cancer Center Walter J Curran, Jr, MD Winship Cancer Institute of Emory University NRG Oncology Lung Cancer Selected Discussion Stage III
More informationIROC Head and Neck Phantom. Guidelines for Planning and Irradiating the IROC IMRT Phantom. Revised MARCH 2014
IROC Head and Neck Phantom Guidelines for Planning and Irradiating the IROC IMRT Phantom. Revised MARCH 2014 The study groups are requesting that each institution keep the phantom for a period of time
More informationIROC Liver Phantom. Guidelines for Planning and Irradiating the IROC Liver Phantom. Revised July 2015
IROC Liver Phantom Guidelines for Planning and Irradiating the IROC Liver Phantom. Revised July 2015 The study groups are requests that each institution keep the phantom for no more than 2 weeks. During
More informationImage Registration: The Challenge for QA Centers
Image Registration: The Challenge for QA Centers Kenneth Ulin, Ph.D. Marcia M. Urie, Ph.D. Quality Assurance Review Center Imaging Studies Used for: Staging Protocol Eligibility Target Volume Definition
More informationThe Clinical Research E-News
ISSUE 18: September 9, 2009 New Activations: The Clinical Research E-News SWOG0518, Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab
More informationNRG ONCOLOGY RTOG 0839
NRG ONCOLOGY RTOG 0839 RANDOMIZED PHASE II STUDY OF PRE-OPERATIVE CHEMORADIOTHERAPY +/- PANITUMUMAB (IND #110152) FOLLOWED BY CONSOLIDATION CHEMOTHERAPY IN POTENTIALLY OPERABLE LOCALLY ADVANCED (STAGE
More informationEligibility Form. 1. Patient Profile. (This form must be completed before the first dose is dispensed.) Request prior approval for enrolment
Bevacizumab in combination with Paclitaxel and Carboplatin - Frontline Treatment (Previously Untreated) Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (This form must be completed before the first
More informationTreatment Planning & IGRT Credentialing for NRG SBRT Trials
Treatment Planning & IGRT Credentialing for NRG SBRT Trials Hania Al Hallaq, Ph.D. Department of Radiation & Cellular Oncology The University of Chicago Learning Objectives Explain rationale behind credentialing
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More information肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
More informationThe Clinical Research E-News
Volume 3: ISSUE 5: March 23, 2011 The Clinical Research E-News Now Open: CALGB 90802, Randomized Phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal
More informationTransperineal Interstitial Permanent Prostate Brachytherapy (TIPPB) Quality Assurance Guidelines
Prostate Brachytherapy QA Page 1 of 1 Transperineal Interstitial Permanent Prostate Brachytherapy (TIPPB) Quality Assurance Guidelines I. Purpose Table of Contents II. III. IV. Background Credentialing
More informationNRG ONCOLOGY RTOG 1201
NRG ONCOLOGY RTOG 1201 A PHASE II RANDOMIZED TRIAL EVALUATING THE ADDITION OF HIGH OR STANDARD INTENSITY RADIATION TO GEMCITABINE AND NAB-PACLITAXEL FOR LOCALLY ADVANCED PANCREATIC CANCER This trial is
More informationRADIATION THERAPY ONCOLOGY GROUP RTOG 0724/GOG-0724
RADIATION THERAPY ONCOLOGY GROUP /GOG-0724 PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE
More informationRadiation Assurance Research Exposure Form
Radiation Assurance Research Exposure Form F1: To be completed by the applicant This section is to be completed by the applicant before submission of the application for Radiation Assurance. The HRA will
More informationNCI Community Oncology Research Program Kansas City (NCORP-KC) RTOG Informed Consent Template for Cancer Treatment Trials (English Language)
Page 1 of 15 NCI Community Oncology Research Program Kansas City (NCORP-KC) RTOG 1112 Informed Consent Template for Cancer Treatment Trials (English Language) RANDOMIZED PHASE III STUDY OF SORAFENIB VERSUS
More informationASTRO Andrew J. Hope, M.D.
IGRT for lung cancer; does XRT dose escalation improve outcome? Jeffrey Bradley, M.D. Associate Professor Department of Radiation Oncology Washington University and The Alvin J. Siteman Comprehensive Cancer
More informationWhat is head and neck cancer? How is head and neck cancer diagnosed and evaluated? How is head and neck cancer treated?
Scan for mobile link. Head and Neck Cancer Head and neck cancer is a group of cancers that start in the oral cavity, larynx, pharynx, salivary glands, nasal cavity or paranasal sinuses. They usually begin
More informationIROC Prostate Phantom. Guidelines for Planning and Treating the IROC IMRT Prostate Phantom. Revised March 2014
IROC Prostate Phantom Guidelines for Planning and Treating the IROC IMRT Prostate Phantom. Revised March 2014 The study groups are requesting that each institution keep the phantom for a period of time
More informationNRG ONCOLOGY RTOG 0631 PHASE II/III STUDY OF IMAGE-GUIDED RADIOSURGERY/SBRT FOR LOCALIZED SPINE METASTASIS
NRG ONCOLOGY RTOG 0631 PHASE II/III STUDY OF IMAGE-GUIDED RADIOSURGERY/SBRT FOR LOCALIZED SPINE METASTASIS Study Chairs (4/14/15) Principal Investigator/Radiation Oncology Samuel Ryu, MD Department of
More informationHead and Neck Cancer. What is head and neck cancer?
Scan for mobile link. Head and Neck Cancer Head and neck cancer is a group of cancers that usually originate in the squamous cells that line the mouth, nose and throat. Typical symptoms include a persistent
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationAllan Price NHS Lothian, Edinburgh, UK
Allan Price NHS Lothian, Edinburgh, UK Radiotherapy Dose Volume Timing Technique PCI Surgery Systemic agents 1 Study Dose Time Induction CT Ann Arbor 65.1-75.6 Gy Duke 73.6-80 Gy RTOG 77.4 Gy 74 Gy 6.5-7.5
More informationAdvanced Technology Consortium (ATC) Credentialing Procedures for 3D Conformal Therapy Protocols 3D CRT Benchmark*
Advanced Technology Consortium (ATC) Credentialing Procedures for 3D Conformal Therapy Protocols 3D CRT Benchmark* Purpose: To evaluate an institution s 3D treatment planning process and the institution
More informationThe Clinical Research E-News
Volume 3: ISSUE 4: March 2, 2011 The Clinical Research E-News Now Open: E1608, A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma E2208, Randomized Phase II Study of
More informationASTRO econtouring for Lymphoma. Stephanie Terezakis, MD
ASTRO econtouring for Lymphoma Stephanie Terezakis, MD Disclosures No conflicts to disclose 1970 Total Lymphoid Irradiation (TLI) 1995 Involved-Field Radiotherapy (IFRT) 2008 Involved Node Radiotherapy
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Imfinzi) Reference Number: CP.PHAR.339 Effective Date: 07.01.17 Last Review Date: 05.18 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important
More informationSUMMARY OF CHANGES INCLUDED IN THE FULL PROTOCOL AMENDMENT OF:
SUMMARY OF CHANGES INCLUDED IN THE FULL PROTOCOL AMENDMENT OF: HPTN 071: Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART): A cluster-randomized trial of the impact of a
More informationThe Clinical Research E-News
Volume 2: ISSUE 11: June 2, 2010 The Clinical Research E-News SPECIAL ALERT: The quarterly CRA Meeting will be held at 8:30am on June 16, 2010 at the Bluemle Science Building room 105. Now Open: SWOG0777,
More informationSBRT fundamentals. Outline 8/2/2012. Stereotactic Body Radiation Therapy Quality Assurance Educational Session
Stereotactic Body Radiation Therapy Quality Assurance Educational Session J Perks PhD, UC Davis Medical Center, Sacramento CA SBRT fundamentals Extra-cranial treatments Single or small number (2-5) of
More informationNRG ONCOLOGY NRG-CC003
NRG ONCOLOGY NRG-CC003 A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer SCHEMA Histologic proof or unequivocal cytologic
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 7: ISSUE 2: February 19, 2015 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials
More informationCombining chemotherapy and radiotherapy of the chest
How to combine chemotherapy, targeted agents and radiotherapy in locally advanced NSCLC? Dirk De Ruysscher, MD, PhD Radiation Oncologist Professor of Radiation Oncology Leuven Cancer Institute Department
More informationAssessing Heterogeneity Correction Algorithms Using the Radiological Physics Center Anthropomorphic Thorax Phantom
Assessing Heterogeneity Correction Algorithms Using the Radiological Physics Center Anthropomorphic Thorax Phantom David Followill, Ph.D. Associate Director Radiological Physics Center RPC History Lesson
More informationLETTER OF AMENDMENT #2 TO: MTN-036/IPM 047. A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings
LETTER OF AMENDMENT #2 TO: MTN-036/IPM 047 A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings Version 1.0, dated 28 June 2017 DAIDS Protocol #30009 IND
More informationThe RPC s Evaluation of Advanced Technologies. AAPM Refresher Course July 29, 2008 Geoffrey S. Ibbott, Ph.D. and RPC Staff
The RPC s Evaluation of Advanced Technologies AAPM Refresher Course July 29, 2008 Geoffrey S. Ibbott, Ph.D. and RPC Staff 1 http://rpc.mdanderson.org Supported by: NCI grants CA10953 and CA81647, and an
More informationIROC Head and Neck Phantom. Guidelines for Planning and Irradiating the IROC IMRT Phantom. Revised April 2014
IROC Head and Neck Phantom Guidelines for Planning and Irradiating the IROC IMRT Phantom. Revised April 2014 The IROC Houston is requesting that each institution keep the phantom for two weeks. During
More informationNRG ONCOLOGY (12/17/14)
NRG ONCOLOGY (12/17/14) RTOG 0232 A PHASE III STUDY COMPARING COMBINED EXTERNAL BEAM RADIATION AND TRANSPERINEAL INTERSTITIAL PERMANENT BRACHYTHERAPY WITH BRACHYTHERAPY ALONE FOR SELECTED PATIENTS WITH
More informationThe OUTBACK Trial. Specific CRF Completion Guidelines
The OUTBACK Trial A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone (ANZGOG 0902, GOG 0274,
More informationNRG ONCOLOGY RTOG 1203 A RANDOMIZED PHASE III STUDY OF STANDARD VS
NRG ONCOLOGY RTOG 1203 A RANDOMIZED PHASE III STUDY OF STANDARD VS. IMRT PELVIC RADIATION FOR POST-OPERATIVE TREATMENT OF ENDOMETRIAL AND CERVICAL CANCER (TIME-C) This trial is part of the National Clinical
More informationJefferson Kimmel Cancer Center Network Presents: The Clinical Research E-News. January 14, 2009
Jefferson Kimmel Cancer Center Network Presents: January 14, 2009 The Clinical Research E-News New Activations at TJU: NCCTG N0723: A Phase III Biomarker Validation Study of Second-Line Therapy in Patients
More informationRADIATION THERAPY ONCOLOGY GROUP RTOG 0438
RADIATION THERAPY ONCOLOGY GROUP RTOG 0438 A PHASE I TRIAL OF HIGHLY CONFORMAL RADIATION THERAPY FOR PATIENTS WITH LIVER METASTASES Translational Research Co-Chair Hany Elsaleh, M.D., Ph.D. UCLA Medical
More informationMulticenter Trial, Phase I Assessment of 2-D FFDM Versus Combo of 2-D and 3-D Tomosynthesis in Breast Cancer Screening
ACRIN PA 4006: Comparison of Full Field Digital Mammography with Digital Breast Tomosynthesis Image Acquisition in Relation to Screening Call-Back Rate Imaging Manual Multicenter Trial, Phase I Assessment
More informationI.2 CNExT This section was software specific and deleted in 2008.
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES FOR HOSPITALS California Cancer Reporting System Standards, Volume I Changes and Clarifications 8th th Edition Revised May 2008 SECTION
More informationCredentialing for the Use of IGRT in Clinical Trials
Credentialing for the Use of IGRT in Clinical Trials James M. Galvin, DSc Thomas Jefferson University Hospital Jefferson Medical College Philadelphia, PA and The Radiation Therapy Oncology Group RADIATION
More informationManage TPS in Research and Education
Manage TPS in Research and Education Wenzheng Feng 12 wef9004@nyp.org; wfeng@med.wayne.edu (1) NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY, (2)Wayne State University,
More informationTMIST: Frequently Asked Questions
TMIST: Frequently Asked Questions Key Topics for Site Investigators and Staff This document answers frequently asked questions about the Tomosynthesis Mammographic Imaging Screening Trial (TMIST/EA1151);
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 6: ISSUE 5: June 12, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials Actively
More informationClinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221. Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS
Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221 Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS 1 Disclosure I have no conflicts of interest to disclose 2 Robotic H&N
More informationDefining Target Volumes and Organs at Risk: a common language
Defining Target Volumes and Organs at Risk: a common language Eduardo Rosenblatt Section Head Applied Radiation Biology and Radiotherapy (ARBR) Section Division of Human Health IAEA Objective: To introduce
More informationIROC Lung Phantom 3D CRT / IMRT. Guidelines for Planning and Irradiating the IROC Lung Phantom. Revised Dec 2015
IROC Lung Phantom 3D CRT / IMRT Guidelines for Planning and Irradiating the IROC Lung Phantom. Revised Dec 2015 The IROC requests that each institution keep the phantom for no more than 2 weeks. During
More informationWhere We Are: NCI s Informed Consent Template and Updates to Address Changing Needs
Where We Are: NCI s Informed Consent Template and Updates to Address Changing Needs Andrea M. Denicoff, MS, RN Cancer Therapy Evaluation Program Division of Cancer Treatment & Diagnosis November 3, 2016
More informationNational Oncologic PET Registry (NOPR) F-18 Fluoride PET Case Report Forms
Form (NOPR) F-18 Fluoride PET Case Report Forms Version Date Patient Information Sheet 06/17/10 (Spanish translation available at: http://www.cancerpetregistry.org/pdf/patient_info_spanish.pdf) Interpreting
More informationUtility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer
Utility of F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Ngoc Ha Le 1*, Hong Son Mai 1, Van Nguyen Le 2, Quang Bieu Bui 2 1 Department
More informationOutline. Contour quality control. Dosimetric impact of contouring errors and variability in Intensity Modulated Radiation Therapy (IMRT)
Dosimetric impact of contouring errors and variability in Intensity Modulated Radiation Therapy (IMRT) James Kavanaugh, MS DABR Department of Radiation Oncology Division of Medical Physics Outline Importance
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationProstate Phantom. Guidelines for Planning and Treating the IMRT Prostate Phantom. Revised March 2014
Prostate Phantom Guidelines for Planning and Treating the IMRT Prostate Phantom. Revised March 2014 GENERAL INFORMATION: Each institution may keep the phantom for a period of time no more than 2 weeks.
More informationFAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated
Page 1 of 5 COG-AEWS1221: Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly
More information4D Radiotherapy in early ca Lung. Prof. Manoj Gupta Dept of Radiotherapy & oncology I.G.Medical College Shimla
4D Radiotherapy in early ca Lung Prof. Manoj Gupta Dept of Radiotherapy & oncology I.G.Medical College Shimla Presentation focus on ---- Limitation of Conventional RT Why Interest in early lung cancer
More informationRTOG 1205 RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VERSUS BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA
RTOG 1205 RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VERSUS BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA This trial is part of the National Clinical Trials Network
More informationRadiotherapy Protocols
Radiotherapy Protocols Cranial Irradiation for Palliative Whole Brain for Metastases and Prophylactic Whole Brain for SCLC Prepared by: Dr C Blesing, Dr N Warner, Dr D Cutter, Ms R Watson, Ms L Drummond,
More informationACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD
ACOSOG Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy Govindan, M.D. Carolyn Reed, MD
More informationNRG ONCOLOGY. NRG-BR001 ClinicalTrials.gov NCT
NRG ONCOLOGY NRG-BR001 ClinicalTrials.gov NCT02206334 A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases This trial is sponsored by the National Cancer Institute
More information